{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035380","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.845184+00:00","generated_at":"2026-06-17T21:05:30.730369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics reports FY2022 net loss of $29.9M; cash runs into Q3 2023; suspends frank relapse enrollment","bullets":["Net loss $29.9M for FY2022, improved from $41.9M in prior year.","Cash and cash equivalents $11.8M at Dec 31, 2022; expected to fund operations into Q3 2023.","Suspended enrollment of frank relapse patients in ARTEMIS trial after no objective responses; re-evaluating modifications.","MT-401 showed MRD+ responses: one patient bridged to transplant, another with 70% PCR reduction; data expected H2 2023.","Wilson Wolf services agreement provided $8M upfront; Lincoln Park equity facility for up to $25M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035380","json":"https://secwatch.observer/filing/0001104659-23-035380.json","markdown":"https://secwatch.observer/filing/0001104659-23-035380.md","text":"https://secwatch.observer/filing/0001104659-23-035380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/0001104659-23-035380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923035380/tm239491d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:05:30.730369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}